Biotech
Commented by André Will-Laudien on June 30th, 2022 | 13:49 CEST
Biotech blockbusters: BioNTech, XPhyto Therapeutics, Valneva, CureVac - What to expect from these stocks?
Now that we have arrived in summer, the pandemic is weakening, and the media presence of the flu disease is also declining. That means less attention for pure-play vaccine makers, and now investors are asking how perhaps alternative money can be made. Is the pipeline of the protagonists strong enough to attract further investor capital, or will the whole industry go underground for the time being? We try our hand at being a truffle pig and dig beneath the surface. Which biotech stock has something up its sleeve?
Read
Commented by Stefan Feulner on June 27th, 2022 | 12:12 CEST
BrainChip and Palantir with strong rebound - How does BioNTech react?
The correction on the stock markets has been going on for months. Technology stocks, in particular, have been hit hard. Due to the end of the ultra-loose monetary policy and possible larger interest rate steps, even market leaders lost more than 80% of their ground in some cases. Whether interest rate hikes can be implemented as planned in the coming months, on the other hand, appears more than questionable. After all, the spectre of recession is already hovering over the capital markets. Moreover, the historical debt levels of several countries are likely to rule out further interest rate hikes.
Read
Commented by Fabian Lorenz on June 23rd, 2022 | 11:35 CEST
Takeover fantasy: +50% in Valneva shares, and what are BioNTech and Defence Therapeutics doing?
Tension is rising in the biotech sector as the takeover merry-go-round spins faster and has now hit Valneva. Pfizer's entry caused the stock to explode 50% in three trading days. Earlier, Pfizer had announced it would acquire migraine specialist Biohaven for USD 11.6 billion. Other pharmaceutical giants are also active: Halozyme wants to swallow Antares Pharma, a specialist in urology and endocrinology, for USD 960 million. The acquisition of Sierra Oncology is costing GlaxoSmithKline around USD 1.9 billion. Like Valneva, Defence Therapeutics is about to start important trials and could attract a major partner. A takeover of BioNTech is unlikely, but the flagship German biotech should also benefit from improved sentiment in the industry. The coming week should be operationally exciting for shareholders.
Read
Commented by Nico Popp on June 22nd, 2022 | 13:01 CEST
Crisis investments? Pharmaceutical stocks in check: Bayer, XPhyto, Pfizer
Many investors want solid foundations for their portfolios when the market is in turmoil. Pharmaceutical stocks have always been considered largely detached from the overall market - after all, our health is not subject to market cycles. We explain whether this assumption is correct and how investors can now invest in stocks from the sector, using three shares as examples.
Read
Commented by Nico Popp on June 22nd, 2022 | 12:32 CEST
Market-independent returns? This is how it's done! Valneva, NervGen, BioNTech
When the stock market is in high gear, it is time for cool heads. Even if many managers are suspected of only having an eye on the next few quarters, there are still some decisions with far-reaching consequences, especially in the case of takeovers and mergers. Most recently, Pfizer acquired a stake in the vaccine manufacturer Valneva. The share price performance to date did not suggest such a step. Here is why the decision could still pay off for shareholders and what signal effect the deal will have.
Read
Commented by Armin Schulz on June 17th, 2022 | 10:45 CEST
BioNTech, Defence Therapeutics, Formycon - Biotech stocks with a lot of future potential
A look at the NASDAQ Biotechnology Index shows that the big hype on biotech companies seems to be over for now. Since September 2021, the index has been falling, repeatedly marking new lows. However, this decline can also be seen as an opportunity because the long-term prospects for the industry are good. People are getting older, and with age comes the diseases that want to be fought. Today we look at three companies with a lot of potential for the future.
Read
Commented by Stefan Feulner on June 16th, 2022 | 11:01 CEST
Biotech stocks ahead of the turnaround - Evotec, NervGen and MorphoSys
Biotechnology stocks could not escape the current correction. The broad-based NASDAQ Biotechnology Index, for example, has lost around 40% since its peak last August. The fact that biotechnology will increasingly become a key technology in the future was already demonstrated during the Corona pandemic when tests, vaccines and drugs were developed in a very short time and made available in large quantities. Thus, more and more capital is likely to move into the sector in the coming years, with great opportunities for the individual companies.
Read
Commented by Nico Popp on June 14th, 2022 | 12:26 CEST
Unheeded crisis signals! What is next: BioNTech, Lufthansa, Triumph Gold
There are always comeback stocks on the stock market. The airports are full of travellers who are being drawn to distant countries. So the tourism industry, and airlines too, could almost strap themselves in for a comeback. If only it weren't for the new BA.5 virus variant, which has infected large parts of the population in Portugal within a very short time. It seems investors have to choose between travel stocks and pandemic stocks when looking for comeback stocks - or is there a laughing third party?
Read
Commented by Armin Schulz on June 10th, 2022 | 11:48 CEST
BioNTech, NervGen Pharma, Valneva - Which stock will make the breakthrough in incurable diseases?
The number of cancer patients increases every year, and only if the disease is detected at an early stage might a cure still be possible. With other diseases such as multiple sclerosis or Alzheimer's, there is no chance of a cure at all. The deterioration progresses slowly and unstoppably. COVID-19 has also shown us how vulnerable humanity is to a virus. But many biotech companies have taken up the fight against these diseases. Any drug that can stop the progression of these diseases would help those affected. Many biotech stocks have corrected significantly recently. Today we take a look at three companies and their existing potential against incurable diseases.
Read
Commented by Juliane Zielonka on June 9th, 2022 | 12:25 CEST
wallstreet:online, Alibaba, Novavax - Digital pioneers and old hands
The number of young investors in Germany is rising steadily. To date, it stands at 49,000 people who are actively involved in their retirement planning. Both private and institutional investors are discovering the field of neobrokers as an investment. wallstreet:online AG is a candidate from the field with its own community. Alibaba founder Jack Ma has recognized that money has to keep moving in order to flow and is launching the first digital bank in Singapore. Things are somewhat more leisurely in the pharmaceutical sector: with Novavax, Americans now have four vaccines to choose from.
Read